The main functions and indications of Sorafenib/Nexavar

Sorafenib/Nexavar (Sorafenib) is an oral targeted drug that is widely used in the treatment of a variety of solid tumors. It belongs to the class of multi-target tyrosine kinase inhibitor drugs. Its mechanism of action involves blocking multiple signaling pathways inside and outside tumor cells, mainly including the Raf/MEK/ERK signaling axis and angiogenesis-related receptors such as VEGFR (vascular endothelial growth factor receptor) and PDGFR (platelet-derived growth factor receptor). By simultaneously inhibiting these kinases, sorafenib can not only effectively prevent the proliferation of tumor cells, but also cut off their blood supply, indirectly causing apoptosis or growth arrest of cancer cells.

In clinical treatment, the main indications of sorafenib include three types of malignant tumors. The first is unresectable advanced liver cancer (HCC), which is one of the earliest indications for which the drug was approved. It is groundbreaking and is one of the important basic drugs for the systemic treatment of advanced liver cancer; the second is advanced renal cell carcinoma (RCC). CC), especially in patients who are ineffective with traditional treatments, sorafenib can significantly delay the progression of the disease; the third is differentiated thyroid cancer (DTC) in which radioactive iodine is ineffective. Sorafenib provides a new treatment option for these patients in the context of limited treatment options. In addition, studies are also exploring the potential indications of sorafenib in other tumor types, such as certain types of lung cancer, breast cancer, etc., but it has not yet been widely approved.

Although sorafenib has certain selectivity as a targeted drug, it may still cause a series of adverse reactions during use, such as hypertension, diarrhea, skin reactions, and hand-foot syndrome. Therefore, close monitoring is required during use and the dose needs to be adjusted according to tolerance. Clinicians will comprehensively evaluate whether sorafenib treatment is suitable based on the patient's basic condition, tumor type, and target expression.

Reference materials:https://www.nexavar.com/